Brings over two decades’ experience leading business development and crafting go-to-market solutions for clinical research organizations
BETHESDA, MD., April 29, 2025 –
Precision for Medicine, a global leader in biomarker-driven clinical research and development, today announced the appointment of Matt Grow as Chief Commercial Officer. In this role, Mr. Grow will focus on implementing a go-to-market strategy that positions Precision for Medicine as the premier partner to help life science companies accelerate clinical research and development.
“We are a leading provider of drug development and commercialization services, bringing specialized capabilities to every stage of clinical development and empowering clients to realize the life-changing potential of their product candidates,” said Chad Clark, President and Chief Operating Officer of Precision Medicine Group. “Matt is an ideal leader to architect our next chapter of growth. With experience leading business development for large CROs and biomarker platforms, Matt intimately understands our clients, and their need for an integrated offering that combines laboratory expertise, clinical trial excellence, and data intelligence. Matt’s expertise will bring tremendous benefit to life science innovators, and we look forward to his many contributions.”
Mr. Grow is a senior leader with over 20 years’ experience in biopharma sales, as well as a proven track record of building collaborative and cohesive teams that help clients deliver life-changing therapies. Mr. Grow joined Precision for Medicine from PathAI, where he served as President of Biopharma and Chief Business Officer and was responsible for leading business development, marketing, and operations across the company’s Translational Medicine, Clinical Trials, Companion Diagnostics and Biopharma Pathology Lab teams. Previously, Mr. Grow spent over 16 years in roles of increasing responsibility at PPD, ultimately serving as Senior Vice President, Global Head of Biopharma Business Development.
“Precision for Medicine has an amazing track record of surrounding clients with the scientific prowess required to bring next generation, life-saving therapies to patients who need them most,” said Mr. Grow. “I am excited to join this team of experienced professionals, who are passionate about solving complex clinical development challenges, and look forward to fostering a culture of commercial innovation and excellence to further extend our reach.”
About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research and development services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies a transformational approach to clinical research that integrates clinical trial design and execution with deep scientific knowledge, laboratory expertise and advanced data intelligence. This convergence is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine Group, with 3,500 people in 40 locations globally across North America, Europe and Asia-Pacific. For more information, visit PrecisionForMedicine.com.
Contact
Brad Epstein
Precision for Medicine
brad.esptein@precisionformedicine.com